Drug intelligence / Profile preview

gonadotropin-releasing hormone agonist + human chorionic gonadotropin

Development stage
Phase 4
Modality
Recombinant Proteins and Enzymes, Peptides
Administration
Subcutaneous, Intramuscular
01

Overview

This drug is a combination of a gonadotropin-releasing hormone (GnRH) agonist and human chorionic gonadotropin (hCG), commonly referred to as the "dual trigger" in assisted reproductive technology. The GnRH agonist stimulates the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), mimicking the natural mid-cycle LH surge required for final oocyte maturation. hCG is administered alongside to further support oocyte maturation and luteal phase function. This combination aims to optimize oocyte maturation, improve pregnancy outcomes, and reduce the risk of ovarian hyperstimulation syndrome compared with hCG alone or GnRH agonist alone[6]. The dual trigger approach is primarily used in controlled ovarian stimulation cycles for in vitro fertilization–intracytoplasmic sperm injection (IVF–ICSI).

Other names
dual triggerGnRH agonist + hCG
02

Targets

GnRHR (Gonadotropin-releasing hormone receptor)LHCGR (Luteinizing hormone/choriogonadotropin receptor)

Beyond the preview

Go deeper on gonadotropin-releasing hormone agonist + human chorionic gonadotropin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gonadotropin-releasing hormone agonist + human chorionic gonadotropin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call